Could a common cholesterol pill be the key to fighting a devastating kidney disease?

NCT ID NCT07282821

First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 26 times

Summary

This study tests whether bempedoic acid, a drug already approved for high cholesterol, can safely slow the progression of autosomal dominant polycystic kidney disease (ADPKD). About 120 adults with rapidly progressing ADPKD will take either the drug or a placebo for two years. The main goals are to check safety and tolerability, and to see if the drug helps preserve kidney function and improve quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADPKD (AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tufts University Medical Center

    Boston, Massachusetts, 02111, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

  • University of Vermont Medical Center

    Burlington, Vermont, 05401, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.